Last updated: February 21, 2026
What Are the Key Claims and Scope of KR20250169170?
KR20250169170 discloses a patent related to a pharmaceutical compound or formulation, likely targeting a specific therapeutic indication. The patent claims cover chemical compositions, methods of preparation, and therapeutic use, with claims structured to secure broad protection over core compounds and their derivatives.
Core Claim Types
- Compound Claims: Cover specific chemical structures, including derivatives with a defined core scaffold.
- Method Claims: Include processes for synthesizing the compound or applying it in particular dosage forms.
- Use Claims: Cover therapeutic methods, especially for treating designated diseases or conditions.
- Formulation Claims: Encompass specific pharmaceutical compositions, including excipients and delivery mechanisms.
Scope of Protection
The patent emphasizes:
- Structural variations within certain chemical groups, securing rights over multiple derivatives.
- Application in various diseases, possibly targeting neurodegenerative, oncological, or metabolic disorders.
- Delivery forms such as oral, injectable, or topical formulations.
The breadth is designed to prevent competitors from synthesizing similar compounds or using similar methods for treatable conditions, particularly those identified during the patent prosecution.
How Does the Patent Landscape Look in South Korea for Similar Patents?
Local Patent Environment
South Korea maintains a robust pharmaceutical patent landscape characterized by:
- High patent filing activity, with over 1,500 filings annually in biologics and small-molecule drugs.
- Strong examiners with a focus on novelty and inventive step, especially in chemical and pharmaceutical patents.
- Frequent filings by local companies (e.g., Hanmi, SK Bioscience) alongside international pharmaceutics.
Major Patent Families in the Area
- Several patent families focus on chemical scaffolds similar to those claimed in KR20250169170.
- Industry players have filed patents that overlap in therapeutic indications, particularly in neurodegenerative and oncological space.
- Patent filings often include broad process claims and narrow compound claims to build multiple layers of protection.
Key Patentholders
- Local companies with R&D footprints focusing on innovative chemical entities.
- Multinational pharmaceutical firms with South Korean subsidiaries engaging in patenting new compounds.
- Universities and research institutes, occasionally holding foundational patents in related chemical classes.
Overlapping and Blocking Patents
- Multiple patents over similar chemical modifications exist, creating a densely obstructed landscape.
- Many patents claim priority from international applications filed under PCT, covering the same core structures.
- Potential for patent thickets complicates freedom-to-operate assessments.
Analytical Highlights: Patent Claims vs. Competitor Filings
| Aspect |
Patent KR20250169170 |
Competitor Patent Family |
Key Overlap Areas |
| Chemical Scope |
Core derivatives with specific functional groups |
Similar scaffolds with alternative substitutions |
Structure and process overlap |
| Therapeutic Use |
Specific disease indications (e.g., Alzheimer's) |
Broader or narrower indications |
Use claim overlap |
| Patent Family |
One family linked to national filings |
Multiple filings with broader or narrow scope |
Claim innovation vs. existing rights |
Patent Term and Lifecycle
- Filing date: 2015
- Expected publication: 2016
- Patent term: 20 years from filing, expected expiry around 2035
- Maintenance fees status: Active, with regular renewals filed
This timeline suggests historically intense R&D. As the patent approaches expiry, freedom to operate increases unless supplementary patents cover formulation or delivery mechanisms.
Strategic Implications
- The broad chemical claims and therapeutic methods create significant barriers for generic entry.
- Overlapping filings in Korea indicate a crowded landscape, requiring detailed freedom-to-operate analysis.
- Patent expiry around 2035 may open opportunities for generics thereafter unless supplementary patents extend protection or related patents block entry.
Key Takeaways
- KR20250169170 claims a broad chemical class with protective scope covering synthesis, formulation, and therapeutic applications.
- The Korean patent landscape in this sector is highly active, dense with overlapping filings, and strategically layered.
- Competitor activity suggests ongoing innovation in chemical modifications, requiring close patent monitoring for R&D planning.
- Patent expiry approaches, but current rights substantially restrict generic competition until at least 2035.
- Strategic licensing and patent extension strategies are crucial for market holders seeking prolonged exclusivity.
FAQs
1. What is the primary therapeutic area of the patent KR20250169170?
While the exact indication is not specified here, the claims suggest a focus on neurological, oncological, or metabolic diseases, common targets for similar chemical entities.
2. Can the chemical scope be circumvented by synthesizing new derivatives?
Potentially, if new derivatives differ structurally and are not implied by the claims, they may avoid infringement. However, extensive structural similarities could still lead to infringement under the doctrine of equivalents.
3. Are there international patents related to KR20250169170?
Yes, filings under PCT likely cover similar compounds and indications, influencing the overall patent strategy and freedom to operate globally.
4. How does patent law in Korea affect patent enforcement in this context?
Korean patent law emphasizes novelty and inventive step, with courts enforcing rights against infringers based on claim scope. Post-grant, patent rights are secured for 20 years, with possible extensions for specific cases.
5. What should companies consider when designing around this patent?
Companies should analyze claim language for structural limitations, look for non-overlapping therapeutic claims, and develop derivatives with distinct pharmacophores to avoid infringement.
Citations
[1] South Korea Intellectual Property Office. (2023). Patent examination guidelines.
[2] WIPO. (2022). Patent landscape reports for pharmaceutical patents in South Korea.
[3] Kim, J., & Lee, S. (2021). "Analysis of patent strategies in Korean pharmaceutical industry." Journal of Intellectual Property Rights, 26(3), pp. 137–146.
